Avidity Biosciences, Inc. — Director's Dealing 2025

Sep 9, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Avidity Biosciences, Inc. (RNA)
CIK: 0001599901
Period of Report: 2025-09-05

Reporting Person: WILSON TROY EDWARD (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-09-05	Common Stock	M	14500	$12.48	Acquired	83925	Direct
2025-09-05	Common Stock	S	14500	$50	Disposed	69425	Direct
2025-09-05	Common Stock	S	15000	$50	Disposed	54425	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-09-05	Stock Option (Right to Buy)	$12.48	M	14500	Disposed	2033-06-14	Common Stock (14500)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	13711	Indirect

Footnotes

F1: All exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 4, 2024.

F2: The option is fully vested and exercisable as of the date hereof.